Avita Medical has signed a joint venture partnership agreement with Kuwait-based Mena United to expands sales of ReCell Spray-On Skin throughout the Middle East and North Africa (MENA).
The ReCell suspension contains basal keratinocytes, melanocytes, fibroblasts and Langerhans cells.
The metabolically responsive epithelial cells migrate across the wound surface and facilitates in regenerating skin of normal color and texture.
Avita Medical claims ReCell Spray-On-Skin allows in-theater preparation of a spray-on suspension consisting of cells derived from a small (2x 2cm), thin (0.15-0.20mm) biopsy of a patient’s own skin that is sufficient to cover an area up to 80 times the size of the biopsy.
Mena United partner Yousef Al-Sultan said with access to Avita’s technology and products, they hope to enhance physicians’ ability to treat burns, wounds and other skin conditions throughout the region.
ReCell is patented, CE-marked for Europe, TGA-registered in Australia and SFDA-cleared in China.
ReCell is an investigational device limited by federal law to investigational use and is not available for sale in the US.